chr9:133588430:> Detail (hg19) (ABL1)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr9:133,588,430-133,763,062 |
hg38 | chr9:130,713,043-130,887,675 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
---|---|---|---|---|---|---|---|---|---|
chronic myeloid leukemia | Dasatinib | B |
![]() |
![]() |
Resistance | Somatic | 3 | 19779040 | Detail |
chronic myeloid leukemia | Bosutinib | B |
![]() |
![]() |
Resistance | Somatic | 3 | 21865346 | Detail |
chronic myeloid leukemia | Nilotinib | B |
![]() |
![]() |
Resistance | Somatic | 3 | 19652056 | Detail |
chronic myeloid leukemia | Bosutinib | B |
![]() |
![]() |
Resistance | Somatic | 3 | 22371878 | Detail |
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
<0.001 | Cardiovascular Diseases | The second-generation tyrosine kinase inhibitor (TKI) of the BCR-ABL1 oncoprotei... | BeFree | 24797802 | Detail |
<0.001 | cerebral palsy | NA | BeFree | Detail | |
0.007 | Congenital chromosomal disease | NA | BeFree | Detail | |
<0.001 | colorectal carcinoma | NA | BeFree | Detail | |
0.003 | Colorectal Neoplasms | NA | LHGDN | Detail | |
0.003 | Cessation of life | NA | LHGDN | Detail | |
<0.001 | diphtheria | NA | BeFree | Detail | |
<0.001 | Down syndrome | NA | BeFree | Detail | |
0.004 | Eosinophilia | To assess the presence of genetic imbalances in patients with myeloproliferative... | BeFree,LHGDN | 24813417 | Detail |
<0.001 | epidermodysplasia verruciformis | NA | BeFree | Detail | |
0.120 | Esophageal Neoplasms | NA | BeFree,CTD_human | Detail | |
<0.001 | Disorder of eye | NA | BeFree | Detail | |
<0.001 | Fanconi anemia | NA | BeFree | Detail | |
<0.001 | gastritis | NA | BeFree | Detail | |
<0.001 | glioblastoma | NA | BeFree | Detail | |
<0.001 | Glioma | NA | BeFree | Detail | |
<0.001 | Graft-vs-Host Disease | NA | BeFree | Detail | |
<0.001 | Graves Disease | NA | BeFree | Detail | |
0.009 | polycythemia vera | In a group of 36 Mexican mestizo patients with MPN, we studied five molecular ma... | BeFree | 19843380 | Detail |
0.008 | Thrombocythemia, Essential | In a group of 36 Mexican mestizo patients with MPN, we studied five molecular ma... | BeFree | 19843380 | Detail |
0.002 | thrombocytosis | In a group of 36 Mexican mestizo patients with MPN, we studied five molecular ma... | BeFree | 19843380 | Detail |
0.001 | Hematological Disease | NA | BeFree | Detail | |
<0.001 | Herpes Simplex Infections | NA | BeFree | Detail | |
0.003 | HIV Infections | NA | BeFree,GAD | Detail | |
0.001 | Immunologic Deficiency Syndromes | Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid ... | BeFree | 25133686 | Detail |
<0.001 | influenza | Nonstructural protein 1 (NS1) proteins from avian influenza viruses like the 191... | BeFree | 25367299 | Detail |
<0.001 | Kidney Failure, Acute | NA | BeFree | Detail | |
0.001 | chronic lymphocytic leukemia | None of the three malignancies shared the same origin, since the marrow sample w... | BeFree | 25648037 | Detail |
<0.001 | Acute Erythroblastic Leukemia | NA | BeFree | Detail | |
0.005 | lymphoid leukemia | High levels of SOCS2 characterize unfavorable subsets of acute myeloid and lymph... | BeFree | 25858143 | Detail |
0.064 | Acute lymphocytic leukemia | The diagnosis of 'Philadelphia like' poor prognosis ALLs is technically challeng... | BeFree | 24848770 | Detail |
0.064 | Acute lymphocytic leukemia | We describe an ultrasensitive electrochemical nucleic acid assay amplified by ca... | BeFree | 24961450 | Detail |
0.064 | Acute lymphocytic leukemia | The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblasti... | BeFree | 24997151 | Detail |
0.064 | Acute lymphocytic leukemia | IKZF1 deletions were associated with B-cell precursor acute lymphoblastic leukem... | BeFree | 25261097 | Detail |
0.064 | Acute lymphocytic leukemia | Tyrosine kinase inhibitors (TKIs) have demonstrated success in the treatment of ... | BeFree | 25415187 | Detail |
0.064 | Acute lymphocytic leukemia | Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and... | BeFree | 25520136 | Detail |
0.064 | Acute lymphocytic leukemia | The depletion of IGF-IR expression in BCR/ABL(+) cells led to the development of... | BeFree | 25648584 | Detail |
0.064 | Acute lymphocytic leukemia | The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 3... | BeFree | 25686603 | Detail |
0.064 | Acute lymphocytic leukemia | In ∼25% of cases, acute lymphoblastic leukaemia (ALL) cells carry the oncogenic ... | BeFree | 25799995 | Detail |
0.064 | Acute lymphocytic leukemia | High levels of SOCS2 characterize unfavorable subsets of acute myeloid and lymph... | BeFree | 25858143 | Detail |
0.064 | Acute lymphocytic leukemia | Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in P... | BeFree | 25895602 | Detail |
0.064 | Acute lymphocytic leukemia | Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. | BeFree | 26321221 | Detail |
0.005 | Leukemia, Lymphocytic, Acute, L1 | We analyzed cells from peripheral blood and CD34-/CD34+ cells from bone marrow o... | BeFree | 25244981 | Detail |
<0.001 | acute biphenotypic leukemia | NA | BeFree | Detail | |
0.023 | Leukemia, Myelocytic, Acute | This case describes a patient with an acute myelogenous leukemia presenting init... | BeFree,LHGDN | 23538898 | Detail |
0.023 | Leukemia, Myelocytic, Acute | Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid ... | BeFree,LHGDN | 24791856 | Detail |
0.023 | Leukemia, Myelocytic, Acute | BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone a... | BeFree,LHGDN | 25401297 | Detail |
0.023 | Leukemia, Myelocytic, Acute | Although tyrosine kinase inhibitors (TKI) can be effective therapies for leukemi... | BeFree,LHGDN | 25547679 | Detail |
0.023 | Leukemia, Myelocytic, Acute | None of the three malignancies shared the same origin, since the marrow sample w... | BeFree,LHGDN | 25648037 | Detail |
0.013 | myeloid leukemia | The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in ... | BeFree,GAD,LHGDN | 25213664 | Detail |
<0.001 | Leukemia, Myeloid, Accelerated Phase | NA | BeFree | Detail | |
0.010 | Leukemia, Myeloid, Chronic-Phase | Here, we studied whether amplicon next-generation deep sequencing (NGS) could im... | BeFree | 25367136 | Detail |
0.010 | Leukemia, Myeloid, Chronic-Phase | After imatinib (IM) treatment, patients with m-bcr showed higher BCR-ABL relativ... | BeFree | 25520136 | Detail |
0.010 | Leukemia, Myeloid, Chronic-Phase | Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievemen... | BeFree | 25530131 | Detail |
0.002 | Leukemia, Myelomonocytic, Chronic | NA | BeFree | Detail | |
0.001 | chronic neutrophilic leukemia | Chronic neutrophilic leukemia (CNL) is a rare BCR-ABL1-negative myeloid malignan... | BeFree | 25575036 | Detail |
0.002 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | NA | BeFree | Detail | |
<0.001 | Adult T-Cell Lymphoma/Leukemia | NA | BeFree | Detail | |
<0.001 | Leukoencephalopathy, Progressive Multifocal | NA | BeFree | Detail | |
0.120 | Liver neoplasms | NA | CTD_human | Detail | |
0.005 | Lung Neoplasms | NA | LHGDN | Detail | |
0.002 | lymphoma | NA | BeFree | Detail | |
<0.001 | Lymphoma, Follicular | NA | BeFree | Detail | |
<0.001 | Lymphoproliferative Disorders | NA | BeFree | Detail | |
0.080 | Memory Disorders | NA | RGD | Detail | |
0.002 | Monosomy | One patient had a complex karyotype including 7 monosomy (-7) and p190 BCR-ABL f... | BeFree | 25300567 | Detail |
0.001 | multiple myeloma | NA | BeFree | Detail | |
0.003 | Muscle hypotonia | NA | LHGDN | Detail | |
0.002 | myelofibrosis | Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neopl... | BeFree | 25520049 | Detail |
0.017 | Myeloproliferative disease | To assess the presence of genetic imbalances in patients with myeloproliferative... | BeFree | 24813417 | Detail |
0.017 | Myeloproliferative disease | The discovery of somatic mutations, primarily JAK2V617F and CALR, in classic BCR... | BeFree | 25151955 | Detail |
0.017 | Myeloproliferative disease | Increased mean platelet volume and immature platelet fraction as potential predi... | BeFree | 25227185 | Detail |
0.017 | Myeloproliferative disease | The diagnosis of the BCR-ABL-negative myeloproliferative neoplasms (MPN), namely... | BeFree | 25349114 | Detail |
0.017 | Myeloproliferative disease | Current data suggest that constitutively active JAK-STAT signaling plays a centr... | BeFree | 25520049 | Detail |
0.017 | Myeloproliferative disease | Discrepancies between bone marrow histopathology and clinical phenotype in BCR-A... | BeFree | 25840747 | Detail |
0.017 | Myeloproliferative disease | RARS-T is a provisional entity in the MDS/MPN (myeloproliferative neoplasm) over... | BeFree | 25899435 | Detail |
0.017 | Myeloproliferative disease | Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by t... | BeFree | 25964959 | Detail |
0.017 | Myeloproliferative disease | Identification of BCR-ABL1 tyrosine kinase as a driver of chronic myeloid leukem... | BeFree | 26062813 | Detail |
0.017 | Myeloproliferative disease | The combined genetic tests of JAK2 V617F, JAK2 exon 12, MPL exon 10, and CALR ex... | BeFree | 26071474 | Detail |
0.017 | Myeloproliferative disease | CML is a myeloproliferative disorder that results from dysregulated tyrosine kin... | BeFree | 26331539 | Detail |
<0.001 | nail-patella syndrome | NA | BeFree | Detail | |
<0.001 | Neoplasm Metastasis | NA | BeFree | Detail | |
0.120 | Neoplasms, Experimental | NA | CTD_human | Detail | |
0.002 | nephroblastoma | NA | BeFree | Detail | |
<0.001 | obesity | NA | BeFree | Detail | |
<0.001 | ovarian carcinoma | NA | BeFree | Detail | |
<0.001 | pancytopenia | NA | BeFree | Detail | |
0.080 | Parkinson disease | NA | RGD | Detail | |
<0.001 | plasmacytoma | NA | BeFree | Detail | |
0.003 | polycythemia | NA | LHGDN | Detail | |
0.009 | polycythemia vera | NA | BeFree,LHGDN | Detail | |
0.120 | Precancerous Conditions | NA | BeFree,CTD_human | Detail | |
0.002 | Preleukemia | NA | BeFree | Detail | |
<0.001 | pulmonary alveolar proteinosis | NA | BeFree | Detail | |
<0.001 | retinoblastoma | NA | BeFree | Detail | |
<0.001 | Retroviridae Infections | NA | BeFree | Detail | |
<0.001 | rubella | NA | BeFree | Detail | |
<0.001 | localized scleroderma | NA | BeFree | Detail | |
<0.001 | systemic scleroderma | NA | BeFree | Detail | |
<0.001 | Sezary syndrome | NA | BeFree | Detail | |
0.008 | Thrombocythemia, Essential | NA | BeFree,LHGDN | Detail | |
<0.001 | thymoma | NA | BeFree | Detail | |
<0.001 | Trisomy | NA | BeFree | Detail | |
<0.001 | tuberous sclerosis | NA | BeFree | Detail | |
0.080 | ureteral obstruction | NA | RGD | Detail | |
<0.001 | Virus Diseases | NA | BeFree | Detail | |
<0.001 | B-Cell Lymphomas | NA | BeFree | Detail | |
<0.001 | Sweet syndrome | This case describes a patient with an acute myelogenous leukemia presenting init... | BeFree | 23538898 | Detail |
0.002 | severe combined immunodeficiency | These findings were also observed in immunodeficient NOD/SCID mice treated with ... | BeFree | 25133686 | Detail |
0.007 | acute leukemia | NA | BeFree | Detail | |
<0.001 | Monocytosis | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma of lung (disorder) | NA | BeFree | Detail | |
<0.001 | esophageal carcinoma | NA | BeFree | Detail | |
<0.001 | Granulocytic Sarcoma | We report a humanized experimental leukemia model where xenografts develop aggre... | BeFree | 24791856 | Detail |
<0.001 | Tumor Progression | NA | BeFree | Detail | |
0.002 | Gastrointestinal Stromal Tumors | NA | BeFree | Detail | |
<0.001 | Anaplastic thyroid carcinoma | NA | BeFree | Detail | |
<0.001 | Papillary thyroid carcinoma | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of lung | NA | BeFree | Detail | |
<0.001 | Parkinsonian Disorders | NA | BeFree | Detail | |
0.017 | Neoplasm, Residual | The Abelson (ABL) gene was the best control gene for quantitative PCR (qPCR)-bas... | BeFree | 23990051 | Detail |
0.017 | Neoplasm, Residual | Despite major advances in the treatment of this highly aggressive disease with p... | BeFree | 25499760 | Detail |
0.017 | Neoplasm, Residual | In chronic myeloid leukemia, the identification of individual BCR-ABL1 fusions i... | BeFree | 25928096 | Detail |
<0.001 | Mucosa-Associated Lymphoid Tissue Lymphoma | NA | BeFree | Detail | |
<0.001 | Acute respiratory failure | NA | BeFree | Detail | |
<0.001 | Spastic syndrome | NA | BeFree | Detail | |
<0.001 | Carcinoma breast stage IV | NA | BeFree | Detail | |
<0.001 | recurrent childhood acute lymphoblastic leukemia | NA | BeFree | Detail | |
<0.001 | relapsing chronic myelogenous leukemia | NA | BeFree | Detail | |
0.007 | Philadelphia chromosome positive chronic myelogenous leukemia | NA | BeFree | Detail | |
0.002 | Philadelphia chromosome negative chronic myelogenous leukemia | NA | BeFree | Detail | |
<0.001 | T-cell childhood acute lymphoblastic leukemia | NA | BeFree | Detail | |
<0.001 | T-cell adult acute lymphoblastic leukemia | NA | BeFree | Detail | |
<0.001 | B-cell adult acute lymphoblastic leukemia | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma Of Esophagus | NA | BeFree | Detail | |
0.002 | Solid tumour | Recently, ABL has also been implicated in the transforming properties of solid t... | BeFree | 25803821 | Detail |
<0.001 | Acute Undifferentiated Leukemia | NA | BeFree | Detail | |
<0.001 | stage, chronic myelogenous leukemia | NA | BeFree | Detail | |
<0.001 | secondary acute myeloid leukemia | NA | BeFree | Detail | |
<0.001 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | NA | BeFree | Detail | |
0.001 | Pre B-cell acute lymphoblastic leukemia | NA | BeFree | Detail | |
0.001 | juvenile myelomonocytic leukemia | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of prostate | NA | BeFree | Detail | |
0.002 | Hematopoietic Neoplasms | BCR-ABL1(+) precursor B-cell acute lymphoblastic leukemia (BCR-ABL1(+) B-ALL) is... | BeFree | 25775523 | Detail |
0.004 | Hematologic Neoplasms | Among these, a very rare fusion transcript joining the first 6 exons of BCR to e... | BeFree | 26149409 | Detail |
<0.001 | Symmetrical dyschromatosis of extremities | NA | BeFree | Detail | |
<0.001 | Chromosome 9, trisomy | NA | BeFree | Detail | |
0.001 | Chromosome 8, trisomy | NA | BeFree | Detail | |
<0.001 | Enteropathy-Associated T-Cell Lymphoma | NA | BeFree | Detail | |
<0.001 | Neurodegenerative Disorders | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of esophagus | NA | BeFree | Detail | |
<0.001 | Thyroid carcinoma | NA | BeFree | Detail | |
0.122 | Carcinogenesis | NA | BeFree,CTD_human | Detail | |
0.012 | Leukemogenesis | Taken together, our results suggest that Grb10 knockdown in vivo leads to impair... | BeFree | 25249015 | Detail |
<0.001 | Lymphoid neoplasm | Here we present methods to study BCR/ABL-triggered leukemia and solid lymphoid t... | BeFree | 25636473 | Detail |
<0.001 | prostate carcinoma | NA | BeFree | Detail | |
0.008 | Thrombocythemia, Essential | Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic... | BeFree | 22847163 | Detail |
0.371 | Myeloid Leukemia, Chronic | Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic... | BeFree | 22847163 | Detail |
0.017 | Myeloproliferative disease | An association between an activating JAK2 mutation (JAK2(V617F)) and BCR/ABL-neg... | BeFree | 16225651 | Detail |
0.009 | polycythemia vera | In the present study, we used mice with a conditional null mutation in the Stat5... | BeFree | 22234689 | Detail |
0.371 | Myeloid Leukemia, Chronic | the BCR-ABL fusion characteristic of chronic myeloid leukemia and the JAK2 V617F... | BeFree | 17285276 | Detail |
0.009 | polycythemia vera | The acquired Janus kinase 2 (JAK2) V617F mutation shows a high frequency in dive... | BeFree | 19167611 | Detail |
<0.001 | Epithelial ovarian cancer | NA | BeFree | Detail | |
0.009 | polycythemia vera | Reliable detection of the JAK2 V617F mutation is a major criterion in the diagno... | BeFree | 20560681 | Detail |
<0.001 | Progressive Neoplastic Disease | NA | BeFree | Detail | |
0.017 | Myeloproliferative disease | Discovery of a constitutively activating point mutation of the Janus kinase 2 (J... | BeFree | 17194663 | Detail |
0.004 | Refractory cancer | Point mutations in the ABL1 kinase domain weaken inhibitor binding and represent... | BeFree | 25686603 | Detail |
0.017 | Myeloproliferative disease | A JAK2(V617F) mutation is frequently found in several BCR/ABL-negative myeloprol... | BeFree | 16670266 | Detail |
0.009 | polycythemia vera | Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregn... | BeFree | 20499211 | Detail |
0.017 | Myeloproliferative disease | Data on angiogenesis in the bone marrow of BCR-ABL1-negative myeloproliferative ... | BeFree | 19466975 | Detail |
0.006 | Primary myelofibrosis | the BCR-ABL fusion characteristic of chronic myeloid leukemia and the JAK2 V617F... | BeFree | 17285276 | Detail |
0.002 | breast carcinoma | In conclusion, the observation that TN breast cancer cell lines respond differen... | BeFree | 25803821 | Detail |
0.033 | Blast Phase | Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor ce... | BeFree | 16442619 | Detail |
0.017 | Myeloproliferative disease | Because JAK2 V617F is specific for myeloid neoplasms, and because it can be dete... | BeFree | 18575049 | Detail |
0.002 | thrombocytosis | Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses... | BeFree | 17285276 | Detail |
0.371 | Myeloid Leukemia, Chronic | Abnormalities of tyrosine kinase proteins are well recognised in myeloid maligna... | BeFree | 21722956 | Detail |
0.006 | Primary myelofibrosis | Reliable detection of the JAK2 V617F mutation is a major criterion in the diagno... | BeFree | 20560681 | Detail |
0.006 | Primary myelofibrosis | The BCR-ABL-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV)... | BeFree | 18769448 | Detail |
0.006 | Primary myelofibrosis | Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential t... | BeFree | 24475114 | Detail |
<0.001 | Carcinoma of lung | NA | BeFree | Detail | |
0.014 | Chronic myeloproliferative disorder | Data on angiogenesis in the bone marrow of BCR-ABL1-negative myeloproliferative ... | BeFree | 19466975 | Detail |
0.014 | Chronic myeloproliferative disorder | The acquired Janus kinase 2 (JAK2) V617F mutation shows a high frequency in dive... | BeFree | 19167611 | Detail |
0.009 | polycythemia vera | Discovery of a constitutively activating point mutation of the Janus kinase 2 (J... | BeFree | 17194663 | Detail |
<0.001 | Malignant neoplasm of kidney | Taken together, our findings demonstrate an unexpected opportunity to repurpose ... | BeFree | 25686603 | Detail |
0.007 | adult acute lymphocytic leukemia | Telomerase activity was significantly lower in Philadelphia chromosome-negative/... | BeFree | 25675863 | Detail |
0.002 | thrombocytosis | NA | BeFree | Detail | |
<0.001 | Leukemia secondary | NA | BeFree | Detail | |
<0.001 | Leukaemia recurrent | NA | BeFree | Detail | |
0.003 | Malignant neoplasm of ovary | NA | BeFree,GAD | Detail | |
<0.001 | sarcoma | NA | BeFree | Detail | |
<0.001 | Chronic leukemia (category) | NA | BeFree | Detail | |
<0.001 | Granulocytosis | NA | BeFree | Detail | |
<0.001 | Precursor T-cell lymphoblastic lymphoma | NA | BeFree | Detail | |
0.011 | Precursor B-cell lymphoblastic leukemia | Expression of CD25 is a specific and relatively sensitive marker for the Philade... | BeFree | 25337274 | Detail |
0.011 | Precursor B-cell lymphoblastic leukemia | BCR-ABL1(+) precursor B-cell acute lymphoblastic leukemia (BCR-ABL1(+) B-ALL) is... | BeFree | 25775523 | Detail |
<0.001 | Chronic myelogenous leukemia, BCR/ABL positive | NA | BeFree | Detail | |
0.001 | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | NA | BeFree | Detail | |
0.014 | Chronic myeloproliferative disorder | To assess the presence of genetic imbalances in patients with myeloproliferative... | BeFree | 24813417 | Detail |
0.014 | Chronic myeloproliferative disorder | The discovery of somatic mutations, primarily JAK2V617F and CALR, in classic BCR... | BeFree | 25151955 | Detail |
0.014 | Chronic myeloproliferative disorder | Increased mean platelet volume and immature platelet fraction as potential predi... | BeFree | 25227185 | Detail |
0.014 | Chronic myeloproliferative disorder | The diagnosis of the BCR-ABL-negative myeloproliferative neoplasms (MPN), namely... | BeFree | 25349114 | Detail |
0.014 | Chronic myeloproliferative disorder | Current data suggest that constitutively active JAK-STAT signaling plays a centr... | BeFree | 25520049 | Detail |
0.014 | Chronic myeloproliferative disorder | Discrepancies between bone marrow histopathology and clinical phenotype in BCR-A... | BeFree | 25840747 | Detail |
0.014 | Chronic myeloproliferative disorder | RARS-T is a provisional entity in the MDS/MPN (myeloproliferative neoplasm) over... | BeFree | 25899435 | Detail |
0.014 | Chronic myeloproliferative disorder | Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by t... | BeFree | 25964959 | Detail |
0.014 | Chronic myeloproliferative disorder | Identification of BCR-ABL1 tyrosine kinase as a driver of chronic myeloid leukem... | BeFree | 26062813 | Detail |
0.014 | Chronic myeloproliferative disorder | The combined genetic tests of JAK2 V617F, JAK2 exon 12, MPL exon 10, and CALR ex... | BeFree | 26071474 | Detail |
0.014 | Chronic myeloproliferative disorder | CML is a myeloproliferative disorder that results from dysregulated tyrosine kin... | BeFree | 26331539 | Detail |
<0.001 | Myelodysplastic-Myeloproliferative Diseases | NA | BeFree | Detail | |
<0.001 | Eosinophilic disorder | To assess the presence of genetic imbalances in patients with myeloproliferative... | BeFree | 24813417 | Detail |
<0.001 | childhood chronic myelogenous leukemia | NA | BeFree | Detail | |
<0.001 | Thymic Lymphoma | NA | BeFree | Detail | |
<0.001 | refractory CML | NA | BeFree | Detail | |
<0.001 | renal carcinoma | Taken together, our findings demonstrate an unexpected opportunity to repurpose ... | BeFree | 25686603 | Detail |
0.123 | Mammary Neoplasms | NA | BeFree,CTD_human,LHGDN | Detail | |
<0.001 | colorectal cancer | NA | BeFree | Detail | |
<0.001 | Disorder characterized by eosinophilia | To assess the presence of genetic imbalances in patients with myeloproliferative... | BeFree | 24813417 | Detail |
0.002 | B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1 | NA | BeFree | Detail | |
<0.001 | OUABAIN RESISTANCE | NA | BeFree | Detail | |
0.005 | MULTICYSTIC RENAL DYSPLASIA, BILATERAL | NA | BeFree | Detail | |
0.001 | campomelic dysplasia | NA | BeFree | Detail | |
<0.001 | HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL, 2 | NA | BeFree | Detail | |
0.006 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | The depletion of IGF-IR expression in BCR/ABL(+) cells led to the development of... | BeFree | 25648584 | Detail |
0.184 | Precursor Cell Lymphoblastic Leukemia Lymphoma | The diagnosis of 'Philadelphia like' poor prognosis ALLs is technically challeng... | BeFree,CTD_human,LHGDN | 24848770 | Detail |
0.184 | Precursor Cell Lymphoblastic Leukemia Lymphoma | The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblasti... | BeFree,CTD_human,LHGDN | 24997151 | Detail |
0.184 | Precursor Cell Lymphoblastic Leukemia Lymphoma | IKZF1 deletions were associated with B-cell precursor acute lymphoblastic leukem... | BeFree,CTD_human,LHGDN | 25261097 | Detail |
0.184 | Precursor Cell Lymphoblastic Leukemia Lymphoma | Tyrosine kinase inhibitors (TKIs) have demonstrated success in the treatment of ... | BeFree,CTD_human,LHGDN | 25415187 | Detail |
0.184 | Precursor Cell Lymphoblastic Leukemia Lymphoma | Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and... | BeFree,CTD_human,LHGDN | 25520136 | Detail |
0.184 | Precursor Cell Lymphoblastic Leukemia Lymphoma | The depletion of IGF-IR expression in BCR/ABL(+) cells led to the development of... | BeFree,CTD_human,LHGDN | 25648584 | Detail |
0.184 | Precursor Cell Lymphoblastic Leukemia Lymphoma | High levels of SOCS2 characterize unfavorable subsets of acute myeloid and lymph... | BeFree,CTD_human,LHGDN | 25858143 | Detail |
0.184 | Precursor Cell Lymphoblastic Leukemia Lymphoma | Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. | BeFree,CTD_human,LHGDN | 26321221 | Detail |
0.001 | Leukemia, B-Cell | NA | BeFree | Detail | |
<0.001 | T-cell prolymphocytic leukemia | NA | BeFree | Detail | |
<0.001 | Promyelocytic leukemia | NA | BeFree | Detail | |
<0.001 | Mixed phenotype acute leukemia | NA | BeFree | Detail | |
<0.001 | myeloid neoplasm | To assess the presence of genetic imbalances in patients with myeloproliferative... | BeFree | 24813417 | Detail |
0.002 | myelodysplastic syndrome | NA | BeFree | Detail | |
<0.001 | FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder) | NA | BeFree | Detail | |
<0.001 | Progressive cGVHD | NA | BeFree | Detail | |
<0.001 | Triple Negative Breast Neoplasms | ABL tyrosine kinase inhibition variable effects on the invasive properties of di... | BeFree | 25803821 | Detail |
0.008 | Infection | NA | LHGDN | Detail | |
0.120 | Leukemia, acute lymphoblastic, susceptibility to, 3 | NA | ORPHANET | Detail | |
0.120 | adenocarcinoma | NA | CTD_human | Detail | |
0.006 | Primary myelofibrosis | The diagnosis of the BCR-ABL-negative myeloproliferative neoplasms (MPN), namely... | BeFree | 25349114 | Detail |
0.006 | Primary myelofibrosis | Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neopl... | BeFree | 25520049 | Detail |
0.002 | Alcoholic Intoxication, Chronic | NA | GAD | Detail | |
0.005 | Alzheimer's disease | NA | GAD,LHGDN | Detail | |
<0.001 | anemia | NA | BeFree | Detail | |
0.003 | Bacterial Infections | NA | BeFree,LHGDN | Detail | |
0.007 | Malignant neoplasm of breast | In conclusion, the observation that TN breast cancer cell lines respond differen... | BeFree,GAD | 25803821 | Detail |
<0.001 | Burkitt lymphoma | NA | BeFree | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myel... | CIViC Evidence | Detail |
In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and ... | CIViC Evidence | Detail |
In this open-label, phase II registration trial, patients that were imatinib resistant (n = 192) or ... | CIViC Evidence | Detail |
This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretr... | CIViC Evidence | Detail |
The second-generation tyrosine kinase inhibitor (TKI) of the BCR-ABL1 oncoprotein nilotinib used in ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
To assess the presence of genetic imbalances in patients with myeloproliferative neoplasms (MPNs), 3... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In a group of 36 Mexican mestizo patients with MPN, we studied five molecular markers: The BCR/ABL1 ... | DisGeNET | Detail |
In a group of 36 Mexican mestizo patients with MPN, we studied five molecular markers: The BCR/ABL1 ... | DisGeNET | Detail |
In a group of 36 Mexican mestizo patients with MPN, we studied five molecular markers: The BCR/ABL1 ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Transferred BCR/ABL DNA from K562 extracellular vesicles causes chronic myeloid leukemia in immunode... | DisGeNET | Detail |
Nonstructural protein 1 (NS1) proteins from avian influenza viruses like the 1918 pandemic NS1 are c... | DisGeNET | Detail |
NA | DisGeNET | Detail |
None of the three malignancies shared the same origin, since the marrow sample was negative for BCR-... | DisGeNET | Detail |
NA | DisGeNET | Detail |
High levels of SOCS2 characterize unfavorable subsets of acute myeloid and lymphoblastic leukemias, ... | DisGeNET | Detail |
The diagnosis of 'Philadelphia like' poor prognosis ALLs is technically challenging but of paramount... | DisGeNET | Detail |
We describe an ultrasensitive electrochemical nucleic acid assay amplified by carbon nanotubes (CNTs... | DisGeNET | Detail |
The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia. | DisGeNET | Detail |
IKZF1 deletions were associated with B-cell precursor acute lymphoblastic leukemia (P=0.036), BCR-AB... | DisGeNET | Detail |
Tyrosine kinase inhibitors (TKIs) have demonstrated success in the treatment of acute lymphoblastic ... | DisGeNET | Detail |
Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic... | DisGeNET | Detail |
The depletion of IGF-IR expression in BCR/ABL(+) cells led to the development of ALL (mostly T cell ... | DisGeNET | Detail |
The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 30-50% of cases of ad... | DisGeNET | Detail |
In ∼25% of cases, acute lymphoblastic leukaemia (ALL) cells carry the oncogenic BCR-ABL1 tyrosine ki... | DisGeNET | Detail |
High levels of SOCS2 characterize unfavorable subsets of acute myeloid and lymphoblastic leukemias, ... | DisGeNET | Detail |
Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymp... | DisGeNET | Detail |
Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. | DisGeNET | Detail |
We analyzed cells from peripheral blood and CD34-/CD34+ cells from bone marrow of pediatric acute ly... | DisGeNET | Detail |
NA | DisGeNET | Detail |
This case describes a patient with an acute myelogenous leukemia presenting initially with heralding... | DisGeNET | Detail |
Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenograf... | DisGeNET | Detail |
BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refract... | DisGeNET | Detail |
Although tyrosine kinase inhibitors (TKI) can be effective therapies for leukemia, they fail to full... | DisGeNET | Detail |
None of the three malignancies shared the same origin, since the marrow sample was negative for BCR-... | DisGeNET | Detail |
The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leuk... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Here, we studied whether amplicon next-generation deep sequencing (NGS) could improve the detection ... | DisGeNET | Detail |
After imatinib (IM) treatment, patients with m-bcr showed higher BCR-ABL relative concentrations in ... | DisGeNET | Detail |
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular respo... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Chronic neutrophilic leukemia (CNL) is a rare BCR-ABL1-negative myeloid malignancy that is character... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
One patient had a complex karyotype including 7 monosomy (-7) and p190 BCR-ABL fusion transcript. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myel... | DisGeNET | Detail |
To assess the presence of genetic imbalances in patients with myeloproliferative neoplasms (MPNs), 3... | DisGeNET | Detail |
The discovery of somatic mutations, primarily JAK2V617F and CALR, in classic BCR-ABL1-negative myelo... | DisGeNET | Detail |
Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic ... | DisGeNET | Detail |
The diagnosis of the BCR-ABL-negative myeloproliferative neoplasms (MPN), namely polycythemia vera, ... | DisGeNET | Detail |
Current data suggest that constitutively active JAK-STAT signaling plays a central role in the patho... | DisGeNET | Detail |
Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myelopr... | DisGeNET | Detail |
RARS-T is a provisional entity in the MDS/MPN (myeloproliferative neoplasm) overlap syndromes, with ... | DisGeNET | Detail |
Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the BCR-ABL oncoprote... | DisGeNET | Detail |
Identification of BCR-ABL1 tyrosine kinase as a driver of chronic myeloid leukemia (CML) and success... | DisGeNET | Detail |
The combined genetic tests of JAK2 V617F, JAK2 exon 12, MPL exon 10, and CALR exon 9 help improve th... | DisGeNET | Detail |
CML is a myeloproliferative disorder that results from dysregulated tyrosine kinase activity of the ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
This case describes a patient with an acute myelogenous leukemia presenting initially with heralding... | DisGeNET | Detail |
These findings were also observed in immunodeficient NOD/SCID mice treated with K562 EVs; BCR/ABL mR... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We report a humanized experimental leukemia model where xenografts develop aggressive acute myeloid ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The Abelson (ABL) gene was the best control gene for quantitative PCR (qPCR)-based diagnosis and min... | DisGeNET | Detail |
Despite major advances in the treatment of this highly aggressive disease with potent inhibitors of ... | DisGeNET | Detail |
In chronic myeloid leukemia, the identification of individual BCR-ABL1 fusions is required for the d... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Recently, ABL has also been implicated in the transforming properties of solid tumors, including tri... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
BCR-ABL1(+) precursor B-cell acute lymphoblastic leukemia (BCR-ABL1(+) B-ALL) is an aggressive hemat... | DisGeNET | Detail |
Among these, a very rare fusion transcript joining the first 6 exons of BCR to exon 2 of ABL1 (e6a2)... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Taken together, our results suggest that Grb10 knockdown in vivo leads to impaired proliferation, lo... | DisGeNET | Detail |
Here we present methods to study BCR/ABL-triggered leukemia and solid lymphoid tumor formation. | DisGeNET | Detail |
NA | DisGeNET | Detail |
Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells, which f... | DisGeNET | Detail |
Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells, which f... | DisGeNET | Detail |
An association between an activating JAK2 mutation (JAK2(V617F)) and BCR/ABL-negative myeloprolifera... | DisGeNET | Detail |
In the present study, we used mice with a conditional null mutation in the Stat5a/b gene locus to de... | DisGeNET | Detail |
the BCR-ABL fusion characteristic of chronic myeloid leukemia and the JAK2 V617F mutation that chara... | DisGeNET | Detail |
The acquired Janus kinase 2 (JAK2) V617F mutation shows a high frequency in diverse BCR/ABL-negative... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Reliable detection of the JAK2 V617F mutation is a major criterion in the diagnosis of BCR/ABL-negat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associ... | DisGeNET | Detail |
Point mutations in the ABL1 kinase domain weaken inhibitor binding and represent the most common cli... | DisGeNET | Detail |
A JAK2(V617F) mutation is frequently found in several BCR/ABL-negative myeloproliferative disorders. | DisGeNET | Detail |
Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polyc... | DisGeNET | Detail |
Data on angiogenesis in the bone marrow of BCR-ABL1-negative myeloproliferative neoplasm (MPN) patie... | DisGeNET | Detail |
the BCR-ABL fusion characteristic of chronic myeloid leukemia and the JAK2 V617F mutation that chara... | DisGeNET | Detail |
In conclusion, the observation that TN breast cancer cell lines respond differently to ABL inhibitor... | DisGeNET | Detail |
Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients wi... | DisGeNET | Detail |
Because JAK2 V617F is specific for myeloid neoplasms, and because it can be detected in peripheral b... | DisGeNET | Detail |
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin b... | DisGeNET | Detail |
Abnormalities of tyrosine kinase proteins are well recognised in myeloid malignancies, mutation in t... | DisGeNET | Detail |
Reliable detection of the JAK2 V617F mutation is a major criterion in the diagnosis of BCR/ABL-negat... | DisGeNET | Detail |
The BCR-ABL-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thromboc... | DisGeNET | Detail |
Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, poly... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Data on angiogenesis in the bone marrow of BCR-ABL1-negative myeloproliferative neoplasm (MPN) patie... | DisGeNET | Detail |
The acquired Janus kinase 2 (JAK2) V617F mutation shows a high frequency in diverse BCR/ABL-negative... | DisGeNET | Detail |
Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associ... | DisGeNET | Detail |
Taken together, our findings demonstrate an unexpected opportunity to repurpose axitinib, an anti-an... | DisGeNET | Detail |
Telomerase activity was significantly lower in Philadelphia chromosome-negative/IKAROS-deleted (BCR-... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BC... | DisGeNET | Detail |
BCR-ABL1(+) precursor B-cell acute lymphoblastic leukemia (BCR-ABL1(+) B-ALL) is an aggressive hemat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
To assess the presence of genetic imbalances in patients with myeloproliferative neoplasms (MPNs), 3... | DisGeNET | Detail |
The discovery of somatic mutations, primarily JAK2V617F and CALR, in classic BCR-ABL1-negative myelo... | DisGeNET | Detail |
Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic ... | DisGeNET | Detail |
The diagnosis of the BCR-ABL-negative myeloproliferative neoplasms (MPN), namely polycythemia vera, ... | DisGeNET | Detail |
Current data suggest that constitutively active JAK-STAT signaling plays a central role in the patho... | DisGeNET | Detail |
Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myelopr... | DisGeNET | Detail |
RARS-T is a provisional entity in the MDS/MPN (myeloproliferative neoplasm) overlap syndromes, with ... | DisGeNET | Detail |
Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the BCR-ABL oncoprote... | DisGeNET | Detail |
Identification of BCR-ABL1 tyrosine kinase as a driver of chronic myeloid leukemia (CML) and success... | DisGeNET | Detail |
The combined genetic tests of JAK2 V617F, JAK2 exon 12, MPL exon 10, and CALR exon 9 help improve th... | DisGeNET | Detail |
CML is a myeloproliferative disorder that results from dysregulated tyrosine kinase activity of the ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
To assess the presence of genetic imbalances in patients with myeloproliferative neoplasms (MPNs), 3... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Taken together, our findings demonstrate an unexpected opportunity to repurpose axitinib, an anti-an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
To assess the presence of genetic imbalances in patients with myeloproliferative neoplasms (MPNs), 3... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The depletion of IGF-IR expression in BCR/ABL(+) cells led to the development of ALL (mostly T cell ... | DisGeNET | Detail |
The diagnosis of 'Philadelphia like' poor prognosis ALLs is technically challenging but of paramount... | DisGeNET | Detail |
The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia. | DisGeNET | Detail |
IKZF1 deletions were associated with B-cell precursor acute lymphoblastic leukemia (P=0.036), BCR-AB... | DisGeNET | Detail |
Tyrosine kinase inhibitors (TKIs) have demonstrated success in the treatment of acute lymphoblastic ... | DisGeNET | Detail |
Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic... | DisGeNET | Detail |
The depletion of IGF-IR expression in BCR/ABL(+) cells led to the development of ALL (mostly T cell ... | DisGeNET | Detail |
High levels of SOCS2 characterize unfavorable subsets of acute myeloid and lymphoblastic leukemias, ... | DisGeNET | Detail |
Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
To assess the presence of genetic imbalances in patients with myeloproliferative neoplasms (MPNs), 3... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negat... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The diagnosis of the BCR-ABL-negative myeloproliferative neoplasms (MPN), namely polycythemia vera, ... | DisGeNET | Detail |
Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myel... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In conclusion, the observation that TN breast cancer cell lines respond differently to ABL inhibitor... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs386626619 dbSNP
- Genome
- hg19
- Position
- chr9:133,588,430-133,763,062
- Variant Type
- snv
- Variant (CIViC) (CIViC Variant)
- TKD MUTATION
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/2371
Genome browser